Novartis AG ADR (NVS)
Novartis AG ADR (NVS) carries a ŷRobot AI score of 68 out of 100. The model's fair value estimate is $177.54, 10.6% above the last close of $160.53. The chart signal reads Hold.
| Metric | NVS |
|---|---|
| AI score | 68 / 100 |
| Chart signal | Hold |
| Fair value estimate | $177.54 |
| Upside to fair value | 10.6% |
| Previous close | $160.53 |
| P/E | 30.74 |
| Price / sales | 5.29 |
| Market cap | $302.86B |
| EPS | 5.24 |
| Revenue growth | 8.0% |
| 1-year price change | 11.2% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, AstraZeneca PLC.
Questions about NVS
Is NVS overvalued or undervalued right now?
As of Oct 30, 2026, ŷRobot's fair-value model estimates Novartis AG ADR (NVS) at $177.54 against a last close of $160.53, implying 10.6% upside to the model's estimate.
Is NVS's chart signal bullish or bearish?
The chart-signal model classifies NVS as Neutral as of Nov 13, 2026, with a signal score of -0.00 on a -1 to 1 scale.
What is NVS's ŷRobot AI score?
NVS scores 68 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is NVS stock expensive on P/E and P/S?
NVS trades at 30.7 times earnings and 5.3 times sales as of Nov 13, 2026.
What does NVS's seasonal forecast show?
ŷRobot's seasonal forecast curve for NVS reads +2.6% at 30 days, +5.2% at 90 days, and +11.2% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is NVS growing?
Novartis AG ADR's revenue growth is +8.0% and free-cash-flow growth is +9.6% on the latest reported figures.
NVS chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.